S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
China Threat Triggers Potential Mining Boom for Investors (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
China Threat Triggers Potential Mining Boom for Investors (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NYSE:MYOV

Myovant Sciences - MYOV Stock Forecast, Price & News

$26.79
-0.07 (-0.26%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$26.70
$26.84
50-Day Range
$16.52
$26.86
52-Week Range
$7.67
$26.90
Volume
512,818 shs
Average Volume
1.03 million shs
Market Capitalization
$2.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33

Myovant Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
20.4% Downside
$21.33 Price Target
Short Interest
Healthy
4.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.40mentions of Myovant Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$422,525 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.82) to ($1.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.00 out of 5 stars

Medical Sector

1037th out of 1,047 stocks

Pharmaceutical Preparations Industry

505th out of 512 stocks

MYOV stock logo

About Myovant Sciences (NYSE:MYOV) Stock

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

MYOV Stock News Headlines

Myovant Sciences (NYSE:MYOV) Reaches New 12-Month High at $26.90
Myovant Sciences: Q2 Earnings Insights
Where Myovant Sciences Stands With Analysts
Here's what Wall Street expects from Myovant Sciences's earnings
Why Myovant Sciences Stock Is Moving Higher
CORRECTION -- Myovant Sciences, Inc.
Myovant Sciences: What The Sumitomo Offer Foretells
See More Headlines
Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

MYOV Company Calendar

Last Earnings
10/26/2022
Today
12/02/2022
Next Earnings (Estimated)
1/25/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:MYOV
Fax
N/A
Employees
407
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.33
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
-20.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-205,980,000.00
Pretax Margin
-50.71%

Debt

Sales & Book Value

Annual Sales
$230.97 million
Book Value
($5.30) per share

Miscellaneous

Free Float
94,964,000
Market Cap
$2.59 billion
Optionable
Not Optionable
Beta
2.24

Key Executives

  • Mr. David C. Marek (Age 57)
    CEO & Director
    Comp: $1.43M
  • Mr. Uneek Mehra (Age 50)
    Principal Financial Officer
    Comp: $631.36k
  • Ms. Lauren Merendino (Age 47)
    Chief Commercial Officer
    Comp: $643.23k
  • Mr. Matthew  Lang J.D.Mr. Matthew Lang J.D. (Age 46)
    Gen. Counsel & Corp. Sec.
  • Mr. Albert Liao
    Director of Corp. Communications
  • Mr. Bryan Selby
    Sr. VP of Product Devel.
  • Dr. Juan Camilo Arjona Ferreira M.D. (Age 52)
    Chief Medical Officer
  • Dr. Teresa Perney Ph.D.
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Andria Langenberg M.D. (Age 65)
    Head of Drug Safety & Pharmacovigilance
  • Mr. Jeffrey D. Nornhold (Age 56)
    Sr. VP of Pharmaceutical Operations & Devel.













MYOV Stock - Frequently Asked Questions

Should I buy or sell Myovant Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYOV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOV, but not buy additional shares or sell existing shares.
View MYOV analyst ratings
or view top-rated stocks.

What is Myovant Sciences' stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month price objectives for Myovant Sciences' stock. Their MYOV share price forecasts range from $10.00 to $27.00. On average, they predict the company's share price to reach $21.33 in the next twelve months. This suggests that the stock has a possible downside of 20.4%.
View analysts price targets for MYOV
or view top-rated stocks among Wall Street analysts.

How have MYOV shares performed in 2022?

Myovant Sciences' stock was trading at $15.57 at the beginning of the year. Since then, MYOV shares have increased by 72.1% and is now trading at $26.79.
View the best growth stocks for 2022 here
.

Are investors shorting Myovant Sciences?

Myovant Sciences saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,070,000 shares, an increase of 18.3% from the October 31st total of 1,750,000 shares. Based on an average daily trading volume, of 1,740,000 shares, the short-interest ratio is currently 1.2 days. Currently, 4.8% of the company's stock are short sold.
View Myovant Sciences' Short Interest
.

When is Myovant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 25th 2023.
View our MYOV earnings forecast
.

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) announced its quarterly earnings data on Wednesday, October, 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The firm had revenue of $104.82 million for the quarter, compared to the consensus estimate of $92 million.

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Bellevue Group AG (6.11%), State Street Corp (2.08%), BlackRock Inc. (1.23%), Vanguard Group Inc. (0.85%), Renaissance Technologies LLC (0.30%) and Hennion & Walsh Asset Management Inc. (0.28%). Insiders that own company stock include Chemical Co Ltd Sumitomo, David C Marek, Ferreira Juan Camilo Arjona, Frank Karbe, Kim Sablich, Lauren Merendino, Matthew Lang, Sciences Ltd Roivant and Uneek Mehra.
View institutional ownership trends
.

How do I buy shares of Myovant Sciences?

Shares of MYOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $26.79.

How much money does Myovant Sciences make?

Myovant Sciences (NYSE:MYOV) has a market capitalization of $2.59 billion and generates $230.97 million in revenue each year. The company earns $-205,980,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

How many employees does Myovant Sciences have?

The company employs 407 workers across the globe.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The official website for the company is www.myovant.com. The company can be reached via phone at 442074003351 or via email at investors@myovant.com.

This page (NYSE:MYOV) was last updated on 12/2/2022 by MarketBeat.com Staff